Stockscreener 앱 받기
403.92
0.63%
2.545
전일 마감가:
$401.37
열려 있는:
$399.945
하루 거래량:
353.64K
Relative Volume:
0.29
시가총액:
$58.22B
수익:
$2.50B
순이익/손실:
$-226.32M
주가수익비율:
-246.11
EPS:
-1.6412
순현금흐름:
$71.51M
1주 성능:
+2.66%
1개월 성능:
+3.36%
6개월 성능:
+100.81%
1년 성능:
+107.14%
1일 변동 폭
$395.33
$408.28
1주일 범위
$383.76
$420.15
52주 변동 폭
$181.00
$437.41
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, IQV
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
403.92 | 58.22B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
666.18 | 246.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
226.07 | 158.93B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
170.26 | 48.00B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
277.55 | 45.68B | 16.63B | 1.39B | 2.12B | 8.0674 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-09 | 재개 | UBS | Buy |
| 2026-09-08 | 개시 | Rothschild & Co Redburn | Buy |
| 2026-06-26 | 재개 | Bernstein | Outperform |
| 2026-06-12 | 재개 | RBC Capital Mkts | Outperform |
| 2026-06-02 | 재개 | Wolfe Research | Outperform |
| 2026-04-14 | 개시 | William Blair | Outperform |
| 2026-01-07 | 개시 | Citigroup | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Natera Director Sheena Jonathan Files to Sell 9,450 Shares Valued at $3.88 Million - Kalkine Media
After a $7.01M September sale, a Natera (NTRA) director proposes another share sale. - Stock Titan
Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Australia
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Nigeria
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com India
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? - Zacks Investment Research
Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Nigeria
Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. - Stock Titan
Natera Director Matthew Rabinowitz Files Form 144 to Sell 50,000 Shares Valued at $19.7M - Kalkine Media
$19.7M in Natera (NTRA) shares is proposed for sale following three September sales. - Stock Titan
Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media
Natera CEO Steven Chapman sells $526k in common stock By Investing.com - Investing.com UK
Natera CEO Steven Chapman sells $526k in common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan. - Stock Titan
Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA). - Stock Titan
After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com UK
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Nigeria
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Zacks Investment Research
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan
Natera (NASDAQ: NTRA) chair unloads stock in preset plan - Stock Titan
Trust tied to Natera (NASDAQ: NTRA) eyes new stock sale after multimillion-dollar trades - Stock Titan
Understanding Momentum Shifts in (NTRA) - Stock Traders Daily
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - webull.com
Natera(NTRA.US) Officer Sells US$16.4 Million in Common Stock - Moomoo
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com South Africa
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - Investing.com
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com India
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - investing.com
Executive chair of Natera (NTRA) sells 50,000 shares - Stock Titan
Insider at Natera (NTRA) plans stock sale, with size detailed in new SEC notice - Stock Titan
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - simplywall.st
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo Finance
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating - Moomoo
Jim Cramer Calls Natera (NTRA) “a Promising Story” - Yahoo Finance
Net current asset value per share of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
3 Reasons Investors Love Natera (NTRA) - TradingView
Fed. Circ. Urged To Overturn Natera's Cancer Test Patent Win - Law360
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) - The Motley Fool
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Natera Inc 주식 (NTRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
Oct 16 '26 |
Sale |
402.47 |
1,500 |
603,710 |
8,250 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Oct 15 '26 |
Option Exercise |
10.41 |
50,000 |
520,500 |
2,169,394 |
| MATTHEW RABINOWITZ | Director |
Oct 15 '26 |
Proposed Sale |
394.75 |
50,000 |
19,737,500 |
0 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Oct 15 '26 |
Sale |
402.64 |
50,000 |
20,132,028 |
2,119,394 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Oct 01 '26 |
Sale |
414.22 |
3,000 |
1,242,645 |
106,914 |
| STEVEN L CHAPMAN | Officer |
Oct 01 '26 |
Proposed Sale |
413.31 |
1,273 |
526,144 |
0 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Oct 01 '26 |
Sale |
413.31 |
1,273 |
526,144 |
96,926 |
| SOLOMON MOSHKEVICH | Officer |
Oct 01 '26 |
Proposed Sale |
414.22 |
3,000 |
1,242,645 |
0 |
| Sheena Jonathan | CO-FOUNDER |
Sep 23 '26 |
Sale |
388.01 |
18,064 |
7,008,972 |
9,000 |
| Sheena Jonathan | Director |
Sep 23 '26 |
Proposed Sale |
387.55 |
21,064 |
8,163,402 |
0 |
2.01%
자본화:
|
볼륨(24시간):